本帖最后由 StephenW 于 2012-11-25 22:25 编辑
Chronic hepatitis B patients with advancedfibrosis/compensated cirrhosis can benefit from peginterferon alfa-2a (40KD): improved or comparable response rates versusmild fibrosis in the phase III studies Reported byJules Levin
Presented atthe 63rd Annual Meeting of the American Association for theStudy of Liver Diseases (AASLD), November 9–13, 2012, Boston, USA
T.Piratvisuth,1P.Marcellin,2E.Gane,3J.Jia,4F.Bonino,5G.Germanidis,6S.Woon Paik,7C.Yurdaydin,8V.Rothe,9L.Regep,10C.Wat,11K-X.Luo,12R.Jin,13Y-F.Liaw14
1NKC Institute of Gastroenterology and Hepatology,Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand; 2Service d’Hépatologie and INSERM CRB3/U773, University Paris-Diderot,Clichy, France; 3New Zealand Liver Transplant Unit, University ofAuckland, Auckland, New Zealand; 4Liver Research Center, Beijing Friendship Hospital,Capital Medical University, Beijing, China; 5Digestive andLiver Disease Division and General Medicine 2 Unit, University Hospital ofPisa, Pisa, Italy; 6First Department of Internal Medicine, AHEPA Hospitalof the Aristotle University Medical School, Thessaloniki, Greece; 7Division of Gastroenterology, Samsung MedicalCenter, Sungkyunkwan University, Seoul, Korea; 8Department ofGastroenterology, University of Ankara Medical School, Ankara, Turkey; 9IST GmbH, Mannheim, Germany; 10F.Hoffmann-La Roche, Basel, Switzerland; 11RocheProducts Limited, Welwyn Garden City, United Kingdom; 12Department of Infectious Diseases, Nanfang Hospital,Guangzhou, China; 13Beijing Friendship Hospital, Capital Medical University,Beijing, China; 14Liver Research Unit, Chang Gung Memorial Hospital,Chang Gung University College of Medicine, Taipei, Taiwan
| 
发表于 2012-11-25 22:24
